ABUS   $4.13  1.23% Market Closed After Close 4.13 0.0

Arbutus Biopharma Corp
Last Events:

2023-08-09 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-08-09 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it crossed the signal line from the top and falls. These factors mean that the market confirms the tendency to fall. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in MACD changed from bearish recovery to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-04 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 5
Target Price Mean 5.00
Mean unverified/preliminary 5.00 / 5.00
Target Price Low / High 4.00 / 7.00
Median / STD DEV 5.00 / 1.22
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Buy Sell Sell
macd Sell None None
stoch None None None
ma20 Sell Sell ActivelyBuy
ma50 None None None
ma100 Sell Sell None
Candlestick PatternSept. 12, 2024 Bearish Three Inside Down - pattern is a made up of three candlesticks. Big white candlestick appears on the first day in a uptrend. The second day body is engulfed by the body of the first day. A black candlestick on the third day with a lower close than the second day. Considered to be a bearish reversal pattern.
ISIN CA03879J1003
ceo Mr. Michael J. McElhaugh
Website https://www.arbutusbio.com
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.